Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

221.20 +4.22 (+1.94%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 03, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

51 Biggest Movers From Yesterday ↗

December 28, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 27, 2021

Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

December 27, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...

Via Benzinga

BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops ↗

December 27, 2021

Patients who received the drug didn't improve in the six-minute walking test.

Via Investor's Business Daily

FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol ↗

December 23, 2021

The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...

Via Benzinga

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗

December 14, 2021

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...

Via Benzinga

Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock ↗

November 22, 2021

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗

November 22, 2021

Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.

Via Investor's Business Daily

Expert Ratings For Alnylam Pharmaceuticals ↗

November 22, 2021

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗

November 22, 2021

Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

November 22, 2021

MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...

Via Benzinga

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan ↗

November 18, 2021

Novo Nordisk is buying an RNA interference company.

Via Investor's Business Daily

Where Alnylam Pharmaceuticals Stands With Analysts ↗

November 01, 2021

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...

Via Benzinga

Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

ALNY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Alnylam Pharmaceuticals Stock Is Tanking This Week ↗

October 29, 2021

The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

66 Biggest Movers From Yesterday ↗

October 29, 2021

Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...

Via Benzinga

Why Alnylam Pharmaceuticals Is Crashing Today ↗

October 28, 2021

The company's earnings fell short of expectations and its CEO is leaving.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 28, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is...

Via Benzinga

Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit ↗

October 28, 2021

Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit.

Via Investor's Business Daily

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

3 Growth Stocks Near 52-Week Highs to Buy Anyway ↗

October 14, 2021

These top performers have what it takes to keep providing outsized gains for patient investors.

Via The Motley Fool

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 12, 2021

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.